Research
Macro partitioning
Orlistat is the least effective registered anti-obesity drug for weight reduction and is associated with significant gastrointestinal side effects.
Orlistat (120 mg three times daily) is available but is considered the least effective registered option for weight loss and is associated with significant gastrointestinal side effects. It is typically used as a third-line treatment.
ModerateRefutesMEDIUM confidence
In Poland, orlistat is predominantly regarded as a third-line medication due to its significant side effects, particularly gastrointestinal issues such as diarrhea, steatorrhea, fecal spotting, abdominal pain, and anal fissures. [...] Moreover, among the three groups of anti-obesity drugs, orlistat is the least effective in reducing weight.[7]
Why this rating
Based on a review of registered drugs and a single study cited.
Source
Pharmacological treatment of obesity: an overview of different groups of anti-obesity drugs available in Poland
Barbara Woch et al. · Journal of Education Health and Sport · 2024
DOI 10.12775/jehs.2024.58.004
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Macro partitioning
- Total daily protein intake of 1.6 g/kg/day is sufficient for maximizing resistance training-induced muscle gains, with an upper confidence interval of 2.2 g/kg/day.Strong
- Resistance exercise training combined with sufficient dietary protein intake acts synergistically to maximize skeletal muscle hypertrophy, with protein intake saturating around 1.6 g/kg/day for general populations and potentially requiring 2.0-2.2 g/kg/day for resistance-trained individuals.Strong
- Trans fats should be completely eliminated from the diet, as they increase LDL cholesterol, decrease HDL cholesterol, and are directly associated with increased coronary risk.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →